Onvansertib in combination with standard of care (SoC) is improving ORR and PFS
KRAS Mutations in mCRC*
* Jones R et al. Br J Cancer. 2017 Mar 28;116(7):923-929
Gaps in KRAS-mutated mCRC therapies present a significant unmet need
40%+ of mCRC patients have a KRAS mutation and therefore do not benefit from targeted therapies (e.g., EGFR inhibitors) in first-line therapy
Current investigational therapies for KRAS-mutated mCRC from Amgen, Mirati only address the G12C mutation, not the most prevalent KRAS mutations
Onvansertib has the potential to address all KRAS mutations because PLK1 activation is downstream of RAS
The prognosis for second-line mCRC patients is poor
For second-line mCRC patients, the 5-year survival rate is 10%
Historical controls showed a 5-13% objective response rate to second-line standard of care FOLFIRI+bevacizumab and a median progression-free survival of 4.5 – 5.7 months
Historical SoC* ORR
Historical SoC* mPFS (months)
* 2008: Bennouna et al., Lancet Oncol 2013; 14: 29–37; 2013: Giessen et al., Acta Oncologica, 2015, 54: 187-193; 2017: Cremolini et al., Lancet Oncol 2020, 21: 497–507; and Antoniotti et al., Correspondence Lancet Oncol June 2020
Patients achieved a strong, durable response with onvansertib + SoC